A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.
Also called NCT02254291
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 308 participants
- Sponsor
- Registry
-
NCT02254291
-
- Main results
- Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02254291. Randomized; no masking; primary purpose treatment. Start 2014-10-02 (actual); primary completion 2015-11-11 (actual). Results posted on 2018-09-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02254291- Content hash
6375938bd1a6c3652adb23ce62de9103d64c97e212c8a49dac79b6b6a377bc63